Navarro-Pérez Jorge, Peiró Salvador, Brotons-Muntó Francisco, López-Alcina Emilio, Real-Romaguera Arcadio
Centro de Salud Salvador Pau, Instituto de Investigación Sanitaria INCLIVA, Valencia, España.
Centro Superior de Investigación en Salud Pública (CSISP-FISABIO), Red de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC), Valencia, España.
Aten Primaria. 2014 May;46(5):231-7. doi: 10.1016/j.aprim.2013.09.005. Epub 2013 Dec 15.
To assess quality of care indicators for benign prostatic hyperplasia (BPH), and to evaluate their strengths and weaknesses for incorporation into health information systems.
Structured expert meeting, using procedures adapted from the nominal group techniques and the Rand consensus method.
Valencian School of Health Studies.
PARTICIPANTS AND/OR CONTEXTS: Forty panellists (74% doctors, 70% from primary care settings) with experience in the management of BPH from 15 departments of the Valencia Health Agency.
Three workshops were held simultaneously (examination and diagnosis, drug therapy, and appropriateness and results), and the 15 quality indicators selected by the coordination group were assessed.
Eleven of the 15 indicators scored in the range of high relevance. The 5 best rated were: the use of alpha-blockers + 5-alpha reductase inhibitor from certain severity level, digital rectal examination in the initial assessment, follow-up with the International Prostate Symptoms Score (IPSS), the rate of urgent catheterization in Hospital Accident & Emergency Units, initial assessment with the IPSS and the use of alpha-blockers prior to catheter removal for acute retention of urine.
Some of the assessed indicators can be useful for incorporation into health information systems.
评估良性前列腺增生（BPH）的护理质量指标，并评估其纳入健康信息系统的优缺点。
结构化专家会议，采用源自名义群体技术和兰德共识方法的程序。
巴伦西亚卫生研究学院。
参与者和/或背景：来自巴伦西亚卫生局15个部门的40名小组成员（74%为医生，70%来自初级保健机构），具有BPH管理经验。
同时举办了三场研讨会（检查与诊断、药物治疗、适宜性与结果），并对协调小组选定的15项质量指标进行了评估。
15项指标中有11项得分显示相关性较高。评分最高的5项指标为：从特定严重程度级别开始使用α受体阻滞剂+5α还原酶抑制剂、初始评估时进行直肠指检、采用国际前列腺症状评分（IPSS）进行随访、医院急诊科紧急导尿率、采用IPSS进行初始评估以及在因急性尿潴留拔除导尿管前使用α受体阻滞剂。
部分评估指标可用于纳入健康信息系统。
